
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.

Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.

The European Commission (EC) has granted its approval for lenvatinib (Kisplyx; EU) in combination with everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy.

To more effectively treat patients with triple negative breast cancer (TNBC), a greater understanding of the disease must first be obtained, said Angela DeMichele, MD, professor of medicine and epidemiology, breast cancer oncologist, University of Pennsylvania.

According to findings of a recent study, obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer (CRC), compared with those without any history of disease.

According to an analysis published in Cancer1, vaginal brachytherapy (VB) has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Results from the phase Ib M13-365 study showed combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

About one quarter of patients (26%) with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance, according to Ju Dong Yang, MD, MSc, at the 10th Annual Conference of the International Liver Cancer Association (ILCA).

Researchers are further exploring the possibility of using an immunotherapeutic vaccinia virus to treat advanced hepatocellular carcinoma (HCC), according to Ghassan K. Abou-Alfa, MD.

Though a new generation of drugs has proved highly effective against the hepatitis C virus (HCV), a leading risk factor for liver cancer in the United States, there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma (HCC) who already have responded to curative treatment.


Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.

Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.

Merck, the manufacturer of pembrolizumab (Keytruda), has announced the FDA has granted priority review to a supplemental biologics license application (sBLA) for the PD-1 inhibitor as a first-line treatment for patients with PD-L1-positive non-small cell lung cancer (NSCLC).

Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it. It was formed by 4 urology practices merging to build a main campus that houses the cancer center and radiation therapy center.

Undergoing surgery to prevent ovarian cancer should depend on familial history, as well as age, according to Maurie Markman, MD.

The upcoming HALO 3013 is the first-ever biomarker-driven trial in pancreatic adenocarcinoma, and could potentially change the treatment paradigm for the disease.

The differentiation between squamous and adenocarcinomas in GI cancer could revolutionize the disease's treatment paradigm, according to John Marshall, MD.

A multicenter trial taking place in Germany seeks to quantify the quality of life for patients with metastatic pancreatic cancer undergoing a combination of nab-paclitaxel and gemcitabine.

<div>The developer of neratinib, Puma Biotechnology, has announced the European Medicines Agency (EMA) has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab (Herceptin).</div>

<div>Though Nivolumab (Opdivo) and ipilimumab (Yervoy) have demonstrated considerable success in the field of metastatic melanoma as both single agents and in combination, questions remain regarding sequencing the agents and the high toxicities that often occur when the 2 immunotherapies are used together.<br /> </div>

Melanoma research is rapidly advancing, explains Jedd D. Wolchok, MD, PhD, particularly with immunotherapy.<br /> <br />

In an interview with <em>Targeted Oncology</em>, Julio Pow-Sang, MD, chair of Urological Oncology at Moffitt Cancer Center, discussed the significance of assessing risk status, options for patients whose risk status falls in a “grey-zone,” and how technology is helping oncologists more accurately characterize risk.

The FDA has approved ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia (CLL). The approval was based on an improvement in progression-free survival (PFS) in the phase III COMPLEMENT-2 study.

According to phase II findings published in <em>The New England Journal of Medicine</em><sup>1</sup>, <sup> </sup>multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate (ORR) of 60% in patients with advanced systemic mastocytosis.

The field of metastatic bladder cancer—an area that had long been stagnant—has quickly evolved with the recent FDA approval of atezolizumab (Tecentriq) coupled with the breakthrough therapy designation of nivolumab (Opdivo).

A new drug application (NDA) has been submitted for brigatinib (AP26113) as a potential treatment for patients with advanced ALK-positive non–small cell lung cancer (NSCLC) following resistance or intolerance to crizotinib (Xalkori).

In an interview with <em>Targeted Oncology</em>, Richard Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discussed the selection of therapies available for patients with metastatic castration-resistant prostate cancer (mCRPC) and the next steps in the field.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for Hispanic men, rates have remained essentially unchanged.

Pfizer has announced plans to acquire the biopharmaceutical company Medivation, which is the developer of the androgen receptor inhibitor enzalutamide (Xtandi). Under the terms of the agreement, Pfizer will pay $81.50 per share in cash for Medivation, totaling approximately $14 billion. Both companies agreed to the transaction, which is expected to complete later this year.